PeptiDream Inc. (4587.T)

2,081.00 +59.00 (+2.92%) At close: 03:15PM JST

PeptiDream Inc.

3-25-23 Tonomachi
Kawasaki-ku
Kawasaki 210-0821
Japan
81 4 4270 1300
https://www.peptidream.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 603

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Patrick Crawford Reid Ph.D.	President, CEO & Representative Director	161.81M	N/A	1975
Dr. Kiyofumi Kaneshiro Ph.D.	CFO, Executive VP & Director	161.81M	N/A	1977
Dr. Keiichi Masuya Ph.D.	COO, Executive VP & Director	161.81M	N/A	1969
Yuko Okimoto	IR & Public Relations Director	N/A	N/A	N/A
Masato Murakami M.B.A., M.D., Ph.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.

Description

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage. The company, through its subsidiary PDRadiopharma Inc., is involved in the research, development, manufacture, sale, export, and import of various radiopharmaceutical and radio diagnostic products. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan.

Corporate governance

PeptiDream Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.